Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase

Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase

Introduction Diabetes is a significant modifiable risk factor for cognitive dysfunction. There are currently no effective treatments that delay or reverse the progression of cognitive dysfunction. Accumulating evidence demonstrates that specific antidiabetes medications hold promise in improving cog...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Liu, Jie Zhang, Wen Zhang, Ying Wang, Lu Zhang, Bing Zhang, Kun Wang, Weili Yan, Yan Bi, Zhou Zhang, Xiang Xu, Wenhui Zhu, Fangyi Li, Xiaoya Zhang, Xiaowei Zhu, Congcong Yu, Huijie Yang, Shihua Chen, Sijue Yang, Beibei Zhai, Tianyu Wu, Shengyi Zhao, Xuewei Tong, Yanjie Duan, Yining Chao, Jindan Wu, Xinhua Ye, Haiyan Cheng
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/8/e095382.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/8/e095382.full

Similar Items